N/A N=27 Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure
Hemorrhoid
Primary: Uneventful Creation of a Functional Staple Line at First Firing of Device — 27 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 Histological Comparison of Ridge Preservation Using Mineralized FDBA Alone Versus a Combined Mineralized-Demineralized Freeze Dried Bone Allograft
Tooth Extraction
Primary: Percent New Vital Bone Formation — 24.7; 36.2 percentage of vital bone
Phase 2 N=26 Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Phase 4 N=19 A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
Autism Spectrum Disorders
Primary: Number of Participants With Reduction in ASD Symptom Severity as Defined by the Social Responsiveness Scale (SRS) — 6 participants
Phase 2 N=19 Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 3 to 7 Hours (AUC3-7hr) After Allergen Challenge Following 9 Days…
Phase 3 N=642 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
Chronic Kidney Disease · Dialysis · Hyperphosphatemia
Primary: The Change in Serum Phosphorus — -0.23; -0.77; -0.97; -0.71 mg/dL
Phase 3 N=294 Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24) — 83.7; 84.5; 55.1 percentage of participants…
Phase 3 N=356 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 28.5; 25.3 months — p=0.2853
Phase 2 N=12 REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Macular Edema · Branch Retinal Vein Occlusion
Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart
N/A N=838 Prospective Study of Veteran Health in Previously Deployed Soldiers
Combat Disorders
Primary: Non-Specific Physical Symptoms — 5.2; 7.9; 7.7; 7.7 units on a scale
Phase 3 N=138 Enhancing Indoor, Community, and Advanced Wheelchair Skills in Spinal Cord Injury (SCI)
Spinal Cord Injury
Primary: Wheelchair Skills Test (WST) — 90.4; 89.6 units on a scale — p=0.001
N/A N=27 A Prospective Study: Alveolar Ridge Augmentation Using Tenting Screws, Acellular Dermal Matrix and Combination Particulate Grafts
Dental Alveolus · Oral Surgical Procedures, Preprosthetic
Primary: Gain in Horizontal Ridge Dimension — 3.33; 3.09 gain in ridge width (mm)
N/A N=282 Do Consumer Providers Enhance Recovery?
Mental Disorder
Primary: BASIS-R — 26.15; 29.34; 24.57; 26.76 units on a scale — p=.5
Phase 1 N=40 A First-in-Human Study of LY3009385 in Healthy Participants
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Drug-related Adverse Events (AEs) or Any Serious AEs — 1; 1; 1; 2 participants
N/A N=287 Dual Diagnosis Self-Help Referral
Dual Diagnosis
Primary: Psychiatric Functioning at 6 Months — .333; .387 units on a scale